HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sore Throat Drugs Heading Behind The Counter In France Over Safety Fears

Executive Summary

France's drugs agency wants to restrict sales of OTC sore throat treatments marketed by Sanofi and others to behind the pharmacy counter due to fears of potential adverse events.

You may also be interested in...

France Wants To Move Paracetamol, Ibuprofen And Aspirin Behind The Counter

France's medicines agency wants to restrict sales of OTC drugs containing paracetamol, ibuprofen and aspirin to behind the pharmacy counter due to safety concerns.

France Reverse-Switches Flurbiprofen Against Backdrop Of NSAID Concerns

France has unexpectedly reverse switched to prescription status flurbiprofen, the active ingredient in Reckitt's Strefen. The move comes shortly after the country's medicines agency warned of serious adverse events related to certain NSAIDs.

France Warns Of Serious Complications Related To OTC Ibuprofen Use

French medicines regulator ANSM warns that use of certain OTC NSAIDs increases the risk of serious complications when suffering from a minor infection. The agency is advising consumers not to use iburofen or ketoprofen to treat pain or fever, and to instead opt for paracetamol. 


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts